Suppr超能文献

复制型HIV-1载体的潜在应用。

Possible applications for replicating HIV 1 vectors.

作者信息

Das Atze T, Jeeninga Rienk E, Berkhout Ben

机构信息

Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection & Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.

出版信息

HIV Ther. 2010 May 1;4(3):361-369. doi: 10.2217/hiv.10.20.

Abstract

Since its discovery some 25 years ago, much has been learned about HIV type 1 and the molecular details of its replication cycle. This insight has been used to develop lentiviral vector systems that have advantages over conventional retroviral vector systems. For safety reasons, the lentiviral vector systems are replication incompetent and the risk of generating a replication competent virus has been minimized. Nevertheless, there may be certain applications for replication competent HIV based vector systems, and we will review our activities in this particular field. This includes the generation of a conditionally replicating HIV 1 variant as a safe live attenuated virus vaccine, the construction of mini HIV variants as cancer selective viruses for virotherapy against leukemia, and the use of a conditionally live anti HIV gene therapy vector. Although safety concerns will undoubtedly remain for the use of replication competent HIV based vector systems, some of the results in cell culture systems are very promising and warrant further testing in appropriate animal models.

摘要

自大约25年前被发现以来,人们对1型艾滋病毒及其复制周期的分子细节已有了很多了解。这些见解已被用于开发慢病毒载体系统,该系统比传统逆转录病毒载体系统具有优势。出于安全考虑,慢病毒载体系统无复制能力,产生具有复制能力病毒的风险已降至最低。然而,具有复制能力的基于艾滋病毒的载体系统可能有某些应用,我们将回顾我们在这一特定领域的活动。这包括产生一种条件性复制的HIV-1变体作为安全的减毒活病毒疫苗,构建微型HIV变体作为用于抗白血病病毒治疗的癌症选择性病毒,以及使用一种条件性活的抗HIV基因治疗载体。尽管使用具有复制能力的基于艾滋病毒的载体系统无疑仍存在安全问题,但细胞培养系统中的一些结果非常有前景,值得在适当的动物模型中进一步测试。

相似文献

1
Possible applications for replicating HIV 1 vectors.
HIV Ther. 2010 May 1;4(3):361-369. doi: 10.2217/hiv.10.20.
2
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.
Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906.
3
Genetic-based therapies to select nonpathogenic variants of HIV-1.
Per Med. 2007 Aug;4(3):261-269. doi: 10.2217/17410541.4.3.261.
4
Can the use of HIV-1 derived gene transfer vectors for clinical application be justified?
Curr Gene Ther. 2004 Mar;4(1):65-77. doi: 10.2174/1566523044578040.
5
Development of replication-competent viral vectors for HIV vaccine delivery.
Curr Opin HIV AIDS. 2013 Sep;8(5):402-11. doi: 10.1097/COH.0b013e328363d389.
6
Conditionally replicating HIV and SIV variants.
Virus Res. 2016 May 2;216:66-75. doi: 10.1016/j.virusres.2015.05.004. Epub 2015 May 15.
7
Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system.
Vaccine. 2016 Jun 24;34(30):3447-53. doi: 10.1016/j.vaccine.2016.05.012. Epub 2016 May 16.
9
Lentiviruses in gene therapy clinical research.
Gene Ther. 2002 Dec;9(24):1730-4. doi: 10.1038/sj.gt.3301893.
10
Strategies for retargeted gene delivery using vectors derived from lentiviruses.
Curr Gene Ther. 2004 Dec;4(4):427-43. doi: 10.2174/1566523043345995.

引用本文的文献

1
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform.
Pharmaceutics. 2022 Dec 29;15(1):121. doi: 10.3390/pharmaceutics15010121.
2
Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.
PLoS One. 2012;7(11):e48848. doi: 10.1371/journal.pone.0048848. Epub 2012 Nov 7.

本文引用的文献

1
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.
Science. 2009 Nov 6;326(5954):818-23. doi: 10.1126/science.1171242.
2
Toward a durable anti-HIV gene therapy based on RNA interference.
Ann N Y Acad Sci. 2009 Sep;1175(1):3-14. doi: 10.1111/j.1749-6632.2009.04972.x.
4
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs.
Mol Ther. 2009 Oct;17(10):1712-23. doi: 10.1038/mt.2009.176. Epub 2009 Aug 11.
5
Targeting cancer-initiating cells with oncolytic viruses.
Mol Ther. 2009 Oct;17(10):1677-82. doi: 10.1038/mt.2009.193. Epub 2009 Aug 11.
9
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905.
10
Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验